Diagnostics News and Research RSS Feed - Diagnostics News and Research

Researchers document accuracy of new tests for rapid diagnosis of drug-resistant forms of RB

Researchers document accuracy of new tests for rapid diagnosis of drug-resistant forms of RB

Researchers at University of California, San Diego School of Medicine have documented the accuracy of three new tests for more rapidly diagnosing drug-resistant forms of tuberculosis (TB), which are much harder and more expensive to treat and which, experts say, represent a major threat to global public health. [More]
IDT to host webinar on high throughput qPCR profiling studies

IDT to host webinar on high throughput qPCR profiling studies

Integrated DNA Technologies will be hosting a webinar to help researchers get the most out of gene expression studies that analyze large numbers of samples. [More]
Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler. [More]
New computational method reveals links between bacterial growth rates and type II diabetes, IBD

New computational method reveals links between bacterial growth rates and type II diabetes, IBD

It is increasingly clear that the thousands of different bacteria living in our intestinal tract - our microbiome - have a major impact on our health. But the details of the microbiome's effects are still fairly murky. [More]
Ascletis completes US$35 million (RMB 220 million) financing

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million. [More]
U-M study suggests potential treatment options for children with aggressive, advanced cancer

U-M study suggests potential treatment options for children with aggressive, advanced cancer

For children with rare, aggressive and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study finds. [More]
Diagnosing traumatic brain injury through a blood test: an interview with Dr Korley

Diagnosing traumatic brain injury through a blood test: an interview with Dr Korley

The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not “mild”. Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don’t. [More]
BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015. [More]

Alere announces cash dividend of $3.00 per share on Series B Convertible Perpetual Preferred Stock

Alere Inc., a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). [More]
Pie Medical Imaging receives 2015 European Frost & Sullivan Award for Technology Leadership

Pie Medical Imaging receives 2015 European Frost & Sullivan Award for Technology Leadership

Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical Imaging (PMI) with the 2015 European Frost & Sullivan Award for Technology Leadership. [More]
Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent. [More]
Special issue of Future Science OA highlights research on protein misfolding diseases

Special issue of Future Science OA highlights research on protein misfolding diseases

Future Science Group today announced the publication of a special issue in Future Science OA, covering the rapidly evolving field of protein misfolding diseases. [More]
New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

About 3% of colorectal cancers are due to Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers. Close blood relatives of patients with Lynch syndrome have a 50% chance of inheritance. The role that PMS2 genetic mutations play in Lynch syndrome has been underestimated in part due to technological limitations. [More]
Researchers design online database to help researchers identify cancer gene mutations

Researchers design online database to help researchers identify cancer gene mutations

Many clinical trials use genome sequencing to learn which gene mutations are present in a patient's tumor cells. The question is important because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine whether there is evidence in the medical literature that particular mutations might drive cancer growth and could be targeted by therapy, and which mutations are of no consequence. [More]
New funding supports pilot study that aims to address national crisis in children's oral health

New funding supports pilot study that aims to address national crisis in children's oral health

Researchers at Plymouth University Peninsula School of Dentistry have received funding of around £150,000 from the Medical Research Council to support a pilot study which aims to go some way towards addressing the national crisis in children's oral health, especially in communities of social deprivation. [More]
TUHS, GE Healthcare collaborate to provide high-quality radiologic imaging services

TUHS, GE Healthcare collaborate to provide high-quality radiologic imaging services

Academic medical centers across the U.S. are experiencing increasing pressure to enhance value - deliver higher quality at lower cost - as they continue to face challenges related to outcomes, cost control, market competition, and other dynamics. Initiatives to promote value typically involve reimbursement arrangements between health insurers and providers that align financial, efficiency and quality incentives. [More]
Researchers discover new hepatitis A-like virus in seals

Researchers discover new hepatitis A-like virus in seals

Scientists in the Center for Infection and Immunity at Columbia University's Mailman School of Public Health have discovered a new virus in seals that is the closest known relative of the human hepatitis A virus. The finding provides new clues on the emergence of hepatitis A. [More]
BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company), today announced it has completed the acquisition of Cellular Research, Inc. [More]
Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center. [More]

Jopari, One Call partner to accelerate workers' compensation workflows for medical practices

Jopari Solutions, Inc. and One Call Care Management have launched a partnership designed to streamline and expedite workers' compensation workflows for busy medical practices. [More]
Advertisement
Advertisement